Evidence map›Paper›PMID 41097719›Full record

ArticleCancers2025

Use of a Pathomics Signature to Predict the Prognosis of Hepatocellular Carcinoma with Cirrhosis: A Multicentre Retrospective Study.

Ting Wang, Jixiang Zheng, Lingling Guo, Jiawen Fan, Yubin Lu, Zhen Peng, Yanfeng Zhong, Zhengjun Zhou, Erbao Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ting WangDepartment of Hepatobiliary and Pancreatic Surgery, Peking University Shenzhen Hospital, Shenzhen 518036, China.
Jixiang ZhengDepartment of General Surgery, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, China.
Lingling GuoDepartment of Radiation Oncology, Peking University Shenzhen Hospital, Shenzhen 518036, China.
Jiawen FanDepartment of Gastrointestinal Surgery, Shenzhen Hospital of Southern Medical University, Shenzhen 518100, China.ORCID 0009-0001-9533-9255
Yubin LuMinimally Invasive Interventional Department, Peking University Shenzhen Hospital, Shenzhen 518036, China.ORCID 0009-0007-5000-9248
Zhen PengDepartment of Hepatobiliary and Pancreatic Surgery, Peking University Shenzhen Hospital, Shenzhen 518036, China.
Yanfeng ZhongCentral Laboratory, Peking University Shenzhen Hospital, Shenzhen 518036, China.
Zhengjun ZhouLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Erbao ChenDepartment of Hepatobiliary and Pancreatic Surgery, Peking University Shenzhen Hospital, Shenzhen 518036, China.

Funding

Guangdong Basic and Applied Basic Research Foundation 2023A1515220200Medical Scientific Research Foundation of Guangdong Province of China A2024351National Natural Science Foundation of China 82303446Science and Technology Development Fund Project of Shenzhen JCYJ20190809095011463Shenzhen High-level Hospital Construction Fund, Peking University Shenzhen Hospital Scientific Research Fund KYQD2023303
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is a highly aggressive and heterogeneous malignancy which predominantly arises in the setting of cirrhosis, and there is lack of models to predict prognosis in cirrhotic HCC. This study aims to develop and validate a prediction model based on the pathomics signature and clinicopathological characteristics to predict the prognosis of HCC with cirrhosis.

methodsIn this multicenter, retrospective study, 389 patients were enrolled (training cohort: 268; independent validation cohort: 121). A total of 351 pathomics features were extracted from digital H-E-stained images, and a pathomics signature (PS

resultsThis study included 389 patients. A 24 feature-based PS

conclusionsThe PS

Indexed as

cirrhosishepatocellular carcinomapathomicsprognosis prediction

Identifiers

PMID41097719
PMCPMC12523728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.